500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 145
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Jay R. Luly Ph.D. | President, CEO & Director | 1,25M | 2,03M | 1956 |
Mr. Paul J. Mellett Jr. | Senior VP of Finance & Administration and CFO | 666,84k | 529,98k | 1955 |
Dr. Yat Sun Or Ph.D. | Senior VP of Research & Development and Chief Scientific Officer | 729,31k | 424,85k | 1952 |
Mr. Nathaniel S. Gardiner J.D. | Consultant | 672,67k | 49,14k | 1954 |
Mr. Brendan Luu | Senior Vice President of Business Development | 622,86k | S.O. | 1975 |
Ms. Jennifer Viera | Senior Director of Investor Relations & Corporate Communications | S.O. | S.O. | S.O. |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
L’ISS Governance QualityScore de Enanta Pharmaceuticals, Inc. en date du 1 mai 2024 est 6. Les scores principaux sont Audit : 3; Société : 4; Droits des actionnaires : 8; Compensation : 7.